S
Sebastian Müller
Researcher at Ansbach
Publications - 3
Citations - 1423
Sebastian Müller is an academic researcher from Ansbach. The author has contributed to research in topics: FOLFIRI & Bevacizumab. The author has an hindex of 3, co-authored 3 publications receiving 1220 citations.
Papers
More filters
Journal ArticleDOI
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
Volker Heinemann,Ludwig Fischer von Weikersthal,Thomas Decker,Alexander Kiani,Ursula Vehling-Kaiser,Salah-Eddin Al-Batran,Tobias Heintges,Christian A. Lerchenmuller,Christoph Kahl,G. Seipelt,Frank Kullmann,Martina Stauch,Werner Scheithauer,Jörg Hielscher,Michael Scholz,Sebastian Müller,Hartmut Link,Norbert Niederle,Andreas Rost,Heinz-Gert Höffkes,Markus Moehler,Reinhard Udo Lindig,Dominik Paul Modest,Lisa Rossius,Thomas Kirchner,Andreas Jung,Sebastian Stintzing +26 more
TL;DR: The association with longer overall survival suggests that FOLFIRI plus cetuximab could be the preferred first-line regimen for patients with KRAS exon 2 wild-type metastatic colorectal cancer.
Journal ArticleDOI
O-0029folfiri plus cetuximab versus folfiri plus bevacizumab as first-line treatment of kras-wildtype metastatic colorectal cancer: german aio study krk-0306 (fire-3)
Dominik Paul Modest,Ludwig Fischer von Weikersthal,Sebastian Stintzing,Thomas Decker,Alexander Kiani,Ursula Vehling-Kaiser,Salah-Eddin Al Batran,Tobias Heintges,Christian A. Lerchenmuller,Christoph Kahl,G. Seipelt,Frank Kullmann,Martina Stauch,Werner Scheithauer,Jörg Hielscher,Michael Scholz,Sebastian Müller,Britta Schäfer,Andreas Jung,Volker Heinemann +19 more
Journal ArticleDOI
Relevance of liver-limited disease in metastatic colorectal cancer: Subgroup findings of the FIRE-3/AIO KRK0306 trial.
Julian Walter Holch,Ingrid Ricard,Sebastian Stintzing,Ludwig Fischer von Weikersthal,Thomas Decker,Alexander Kiani,Ursula Vehling-Kaiser,Salah-Eddin Al-Batran,Tobias Heintges,Christian A. Lerchenmuller,Christoph Kahl,Frank Kullmann,Werner Scheithauer,Michael Scholz,Sebastian Müller,Hartmut Link,Andreas Rost,Heinz-Gert Höffkes,Markus Moehler,Reinhard Udo Lindig,Lisa Miller-Phillips,Thomas Kirchner,Andreas Jung,Jobst C. von Einem,Dominik Paul Modest,Volker Heinemann +25 more
TL;DR: LLD could be identified as a prognostic factor in RAS‐WT mCRC, which was independent of hepatic resection in patients treated with targeted therapy, and treatment benefit from FOLFIRI plus cetuximab over bevacizumab wasindependent of LLD status.